Canada markets closed

Marvel Biosciences Corp. (MRVL.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.1450+0.0050 (+3.57%)
At close: 03:26PM EST

Marvel Biosciences Corp.

505 8th Avenue S.W.
Suit 420
Calgary, AB T2P 1G2
Canada
403 770 2469
https://marvelbiotechnology.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. J. Roderick MathesonPres, CEO & Exec. Chairman147kN/AN/A
Dr. Mark Williams M.B.A., Ph.D.Chief Science Officer & Director150kN/A1972
Mr. Harpreet Nijjar C.M.A., CPAChief Financial OfficerN/AN/A1988
Ms. Jacqueline GrootCorp. Sec.N/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Marvel Biosciences Corp. operates as a pre-clinical stage pharmaceutical development biotechnology company. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The company offers Nourianz (Istradefylline, KW-6002), an adenosine A2A receptor antagonist. It targets neurological diseases, such as Alzheimer's disease, depression and anxiety, and addictions; non-neurological conditions of cancer; and non-alcoholic steatohepatitis. Marvel Biosciences Corp. is headquartered in Calgary, Canada.

Corporate Governance

Marvel Biosciences Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.